PubMed Health⌕ Search

Biomedical subjects

J Segreti

Publications and source records attributed to J Segreti.

At least 37 records · Page 2Linked to original sources
PubMed1994

In vitro activity of dirithromycin against Chlamydia trachomatis.

Dirithromycin is a new macrolide antibiotic with an active metabolite, erythromycylamine. We evaluated the in vitro activities of both drugs against 16 isolates of Chlamydia trachomatis and compared them with that of doxycycline. In vitro susceptibility testing was performed with McCoy cell monolayers. The MIC was defined as the lowest concentration of antibiotic without inclusions. The MBC was defined as the lowest concentration of antibiotic yielding no inclusions after passage onto 24-h-old antibiotic-free McCoy cell monolayers. Dirithromycin and erythromycylamine appeared to be equally effective against these 16 strains of C. trachomatis (MIC for 90% of strains tested, 1 mg/ml; MBC for 90% of strains tested, 2 micrograms/ml). Both were less active than doxycycline (MIC for 90% of strains tested, 0.06 micrograms/ml; MBC for 90% of strains tested, 0.12 micrograms/ml). The combination of dirithromycin and erythromycylamine appeared to be additive.

Anti-Bacterial Agents↗
PubMed1993

In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.

The in vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents was investigated. The antimicrobial agents evaluated included ceftizoxime, FK037, cefotaxime, dirithromycin, clarithromycin and its metabolite 14-hydroxy-clarithromycin, erythromycin, doxycycline, amoxicillin, ciprofloxacin, and ofloxacin. Isolates of B. burgdorferi tested included two reference strains (B31 and ATCC 53899), six isolates from the midwestern United States, and three from Europe. A broth macrodilution method was used to determine MICs and MBCs. B. burgdorferi was inhibited by < or = 0.5 micrograms of each of the agents except the quinolones per ml. The MBCs for 90% of strains tested of ceftizoxime, FK037, clarithromycin, 14-OH clarithromycin, and dirithromycin (< or = 1.0 microgram of each per ml) were superior to those of amoxicillin (2.0 micrograms/ml) and doxycycline (4.0 micrograms/ml). Further in vivo studies are warranted to determine whether these agents may be efficacious in the treatment of Lyme borreliosis.

Anti-Bacterial Agents↗
PubMed1992

High-level quinolone resistance in clinical isolates of Campylobacter jejuni.

During a recent clinical trial of ciprofloxacin in the therapy of acute diarrhea, two subjects infected with Campylobacter jejuni who received ciprofloxacin failed microbiologically and one also failed clinically. Although both pretreatment isolates were susceptible to ciprofloxacin, the posttreatment isolates were resistant to ciprofloxacin (MIC = 32 micrograms/ml) and to other quinolones. The posttreatment isolates remained susceptible to nonquinolone antimicrobials. DNA gyrase holoenzyme was isolated from one of the resistant posttreatment isolates and was 8- to 16-fold less sensitive to inhibition by ciprofloxacin than was the gyrase from the paired pretreatment susceptible isolate. Ciprofloxacin accumulation was diminished in the two resistant posttreatment isolates. These results show that mutation in C. jejuni can occur in vivo and is associated with clinically significant resistance to the newer quinolones.

Anti-Infective Agents↗
PubMed1992

An outbreak of Serratia marcescens in 14 adult cardiac surgical patients associated with 12-lead electrocardiogram bulbs.

Two clusters of Serratia marcescens in 14 adult cardiac surgical patients occurred over 10 months in an 876-bed teaching hospital. The 14 infections that were studied were as follows: one sternal and five leg incisions, five pneumonias, one bacteremia, one urinary tract infection, and one infected internal defibrillator site. The first cluster included four pneumonias, one urinary tract infection, and one bacteremia. Corrective actions were taken based on outbreak data through no source was identified. No further infections occurred during the following 2 months. The second cluster included one sternal and five leg incisions, an infected internal defibrillator incision site, and one pneumonia. Serratia marcescens was isolated from six electrocardiogram rubber welsh bulbs with sensitivities identical to patient isolates that indicated a common source outbreak in at least the second cluster of infections. Disposable electrocardiogram leads were introduced and the problem was resolved. We conclude that reusable electrocardiogram welsh bulbs are a vector for postoperative infections.

Aged↗
PubMed1991

In vitro activity of temafloxacin against pathogens causing sexually transmitted diseases.

The fluoroquinolones represent a new therapeutic alternative for the treatment of many sexually transmitted diseases, especially those caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, and Urea-plasma urealyticum. In vitro studies have demonstrated the 90% minimal inhibitory concentrations (MIC90s) of temafloxacin for these pathogens to be less than 0.03 micrograms/mL for N. gonorrhoeae; 0.25 micrograms/mL for C. trachomatis; 0.125-2 micrograms/mL for M. hominis; and 4 micrograms/mL for U. urealyticum. These concentrations are equal to or less than those achievable in plasma following a 400-mg temafloxacin oral dose given twice daily. Based on temafloxacin's antimicrobial activity and pharmacokinetic profile, it appears to be an excellent agent for the treatment of patients with gonococcal or nongonococcal urethritis and/or cervicitis.

Anti-Infective Agents↗
PubMed1991

Fluoroquinolones for the treatment of nongonococcal urethritis/cervicitis.

Approximately 50% of cases of nongonococcal urethritis reported among men are caused by Chlamydia trachomatis. Other pathogens implicated in the bacterial etiology of nongonococcal urethritis that occur independently or concurrently with gonorrhea include Ureaplasma urealyticum and species of Mycoplasma, including Mycoplasma hominis. The etiology of up to half of the cases, however, remains uncertain. Historically, C. trachomatis genital infections have been difficult to diagnose because of the need for expensive cell-culture methods that are technically difficult and produce delayed results. In addition, women with nongonococcal cervicitis/mucopurulent cervicitis are frequently asymptomatic except for vaginal discharge. Nongonococcal urethritis may also be asymptomatic in men. Increased morbidity is associated with unidentified and untreated C. trachomatis infections, especially in women and children. Currently, the Centers for Disease Control recommends that all patients diagnosed with nongonococcal urethritis, nongonococcal cervicitis, or gonorrhea--along with their sexual partners--receive adequate antimicrobial therapy that includes antimicrobial activity against chlamydiae. A tetracycline antibiotic is most commonly recommended. However, tetracyclines have variable in vitro activity against U. urealyticum and Mycoplasma species. New antibiotic therapy options with broader antimicrobial coverage are needed for the management of nongonococcal urethritis and cervicitis.

Anti-Infective Agents↗
PubMed1990

In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogens.

The in vitro activity of tosufloxacin (A-61827; T-3262) against 15 clinical isolates of Chlamydia trachomatis and 31 recent clinical isolates of Neisseria gonorrhoeae, including 15 spectinomycin-resistant N. gonorrhoeae and 16 penicillinase-producing N. gonorrhoeae, was determined. Tosufloxacin was compared with doxycycline, ciprofloxacin, and temafloxacin against C. trachomatis. Susceptibility testing was performed by using McCoy cell monolayers. The in vitro activity of tosufloxacin against N. gonorrhoeae was compared with that of ciprofloxacin, temafloxacin, doxycycline, ceftriaxone, and spectinomycin by using an agar dilution method. Tosufloxacin was as active as temafloxacin against C. trachomatis (MIC for 90% of strains tested [MIC90], 0.25 microgram/ml; MBC for 90% of strains tested [MBC90], 0.25 microgram/ml) and was almost as active as doxycycline (MIC90, 0.06 microgram/ml; MBC90, 0.125 microgram/ml). Ciprofloxacin, temafloxacin, and tosufloxacin were extremely active against N. gonorrhoeae, including spectinomycin-resistant N. gonorrhoeae and penicillinase-producing N. gonorrhoeae, with MIC90s of 0.004, 0.015, and 0.008 microgram/ml, respectively. Ceftriaxone was slightly less active (MIC90, 0.03 microgram/ml), and doxycycline was the least active drug tested (MIC90, 4.0 micrograms/ml). Tosufloxacin and temafloxacin had excellent activity against the C. trachomatis and N. gonorrhoeae strains tested.

4-Quinolones↗
PubMed1990

Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults.

From June 1985 to September 1987, 202 adults were enrolled in a randomized, double-blinded study comparing ciprofloxacin (500 mg) with sulfamethoxazole and trimethoprim (160 mg/800 mg) or placebo for adults with acute diarrhea. All patients were treated on the day of presentation and received medication on a twice-daily schedule (every 12 hours) for 5 days. Bacterial isolates from these patients included 35 Campylobacter, 18 Shigella, and 15 Salmonella. Treatment at the time of presentation with ciprofloxacin compared with placebo shortened the duration of diarrhea (2.4 vs 3.4 days), and increased the percentage of patients cured or improved by treatment days 1, 3, 4, and 5. Similar significant differences for sulfamethoxazole and trimethoprim compared with placebo were not seen.

Adult↗
PubMed1989

In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea.

The in vitro activities of temafloxacin (A63004) and lomefloxacin (SC-47111; NY-198) were compared with those of seven other antibiotics against 146 isolates of bacterial enteric pathogens, including Campylobacter jejuni and Campylobacter coli. Ciprofloxacin was the most active drug against the Salmonella, Shigella, Yersinia, and Vibrio spp. tested. Lomefloxacin, temafloxacin, and difloxacin were the most active drugs tested against Campylobacter spp. (MIC for 90% of strains, 0.125 to 0.25 micrograms/ml).

4-Quinolones↗
PubMed1989

Nosocomial infections and secondary infections in sepsis.

Hospital-acquired infection remains an important cause of morbidity and mortality. Many of the measures used in the diagnosis and therapy of septic shock may predispose the patient to such infections. Selected aspects of secondary infection in patients with septic shock syndrome are reviewed.

Cross Infection↗
PubMed1989

The role of prophylactic antibiotics in the prevention of prosthetic device infections.

This article examines available information concerning the use of antimicrobial agents to prevent prosthetic device infection at the time of surgical implantation. Additionally, the authors comment on the dearth of information concerning prophylactic antibiotics prior to elective surgical or dental procedures to prevent contamination of prosthetic devices already in place.

Anti-Bacterial Agents↗
PubMed1987

Comparative in vitro activity of A-56268 (TE-031) against gram-positive and gram-negative bacteria and Chlamydia trachomatis.

The in vitro activity of A-56268 (TE-031) was determined and compared with that of 13 antibiotics against 401 gram-positive and gram-negative bacteria and 11 strains of Chlamydia trachomatis. A-56268 was very active against methicillin-susceptible Staphylococcus aureus and Neisseria gonorrhoeae, and was among the most active of the agents tested against Listeria monocytogenes, streptococci and Chlamydia trachomatis. It was moderately active against Haemophilus spp., Vibrio spp., Campylobacter jejuni and Campylobacter fetus subsp. fetus. It was inactive against enterococci, methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, Campylobacter coli, Salmonella spp., Shigella spp. and Yersinia enterocolitica. A-56268 was not consistently bactericidal or more active than erythromycin for any organism except Chlamydia trachomatis.

Animals↗
PubMed1987

In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms.

The in vitro activity of A-56268 was determined and compared with that of erythromycin and clindamycin against a limited spectrum of 401 gram-positive and gram-negative organisms. A-56268 was quite active against erythromycin-susceptible Staphylococcus aureus, Neisseria gonorrhoeae, Listeria monocytogenes, Streptococcus pneumoniae, Streptococcus pyogenes, and group B streptococci and was moderately active against Campylobacter fetus subsp. fetus. A-56268 was consistently bactericidal only for S. pneumoniae. The activity of A-56268 was comparable to that of erythromycin against most organisms tested.

Anti-Bacterial Agents↗
PubMed1987

Overwhelming pneumonia.

Overwhelming pneumonias remain an important cause of morbidity and mortality. These illnesses may be rapidly fatal; thus, many patients are treated empirically. Although the various etiologic agents cannot be differentiated on the basis of radiographic appearance, epidemiologic information may give a clue to the cause. Community-acquired overwhelming pneumonias are usually due to pyogenic bacteria (especially Streptococcus pneumoniae), mycoplasma, mycobacteria, and fungi. Hospital-acquired pneumonias are usually due to aerobic gram-negative bacilli. If the patient is immunocompromised, Pneumocystis carinii, Candida, and Aspergillus must be considered. Choice of optimal antimicrobial therapy requires that a specific etiology be identified. Gram's stain of sputum is often helpful in the diagnosis of community-acquired pneumonia. Invasive diagnostic techniques such as bronchoscopy and open lung biopsy are often required in nosocomial pneumonias and pneumonias in immunocompromised patients.

Acquired Immunodeficiency Syndrome↗